Keytruda in conjunction with Lenvima for liver cell carcinoma (HCC): Encountering Waterloo
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Merck and Japan's Aoki corporation signed today thatFDAissued a complete response letter to requests for accelerated approval of Keytruda and Lenvatinib for first-line treatment of patients with hepatocellular carcinoma (HCC) who cannot be removed, and the FDA said in the letter that there is no evidence that this combination has a clear advantage over existing therapies, the FDA approved Roche's PD-L1 inhibitor Tecentriq (atezolizumab) joint Avastin (bevamonotag) treatment for HCC patients who were unsurgical or had not previously received systemic treatmentCompared to Nexavar (Sorafenib), the overall survival rate and progression-free survival rates of patients in the joint programme group of Tecentriq (atezolizumab) and Avastin (Bevamonox) have improved significantlyMerck and Japan's Aoki Applied for Applications are based on data from the Ib KEYNOTE-524 / Study 116 trial, which showed an objective response rate of 36% for patients in the Keytruda and Lenvima combined treatment groupsThe companies said they plan to work with the FDA to take appropriate next stepsHCC is the most common type of chronic liver cancer in adults and is the most common cause of death in patients with cirrhosisIt occurs in an environment with chronic liver inflammation and is highly associated with chronic toxic hepatitisinfection seis(hepatitis B or C), alcohol or toxins (e.gaflatoxin)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
